Polyomavirus JC, multiple sclerosis, Tysabri, and an anti-malaria drug
Biogen has announced that an anti-malaria compound may be useful for treating a brain infection, progressive multifocal leukoencephalopathy (PML), that is an adverse effect of the company’s multiple sclerosis/Crohn’s disease drug Tysabri. How does JC virus fit into this story? Tysabri is the trade name for Natalizumab, a monoclonal antibody against the cellular protein alpha-4 integrin. …
Polyomavirus JC, multiple sclerosis, Tysabri, and an anti-malaria drug Read More »